CJC-1295 with DAC (Research Use Only)

CJC-1295 with DAC is a synthetic peptide analog commonly used in research settings to study GHRH (growth hormone–releasing hormone) receptor signaling and downstream activity within the GH/IGF-1 axis. The “DAC” (Drug Affinity Complex) modification is investigated for its ability to extend peptide persistence in experimental systems, making this compound useful in protocols where researchers want to observe longer-duration signaling effects compared to non-DAC GHRH analogs.

Research Applications & Study Interest

CJC-1295 with DAC is often utilized in in vitro and preclinical models to evaluate:

• GHRH receptor pathway activity: mapping receptor-mediated signaling related to GH release mechanisms (model-dependent)

• Pituitary signaling research: studying response patterns and biomarker shifts associated with pituitary pathway stimulation

• GH/IGF-1 axis biomarkers: tracking experimental readouts tied to growth-hormone signaling cascades

• Signal duration and persistence studies: comparing DAC vs non-DAC analogs for sustained pathway activation in controlled models

• Endocrine pathway modeling: exploring broader hormonal signaling networks and feedback mechanisms (assay- and model-specific)

Mechanism of Research Interest (High-Level)

CJC-1295 is designed to interact with GHRH receptors, supporting research into signaling that may influence growth hormone–associated pathways. The DAC component is studied for how it can affect:

• Binding/affinity dynamics in experimental systems

• Peptide stability and clearance timing (model-dependent)

• Duration of downstream signaling measured via lab assays

Observed outcomes vary based on model selection, assay type, preparation, and experimental controls.

Typical Research Formats

• Commonly supplied as a lyophilized powder for controlled laboratory preparation

• Researchers may verify identity/purity using HPLC/LC-MS depending on protocol requirements